To recover your password please fill in your email address
Please fill in below form to create an account with us
OUR IMPACT
33% improvement in overall survival and a 60% improvement in progression-free survival for people with hormone-sensitive prostate cancer. Recognised as one of the most important clinical research advances in 2020.
|
ORIGIN |
Approximately 3,300 people died from prostate cancer in Australia in 2019. Survival rates are high, with a 95% chance of surviving at least five years from the date of diagnosis. |
|
STUDY OVERVIEW |
The aim of the study was to see if a new drug, enzalutamide, can improve outcomes for patients with metastatic prostate cancer compared with the current best standard treatment. This was a randomised controlled trial meaning that half the trial participants received enzalutamide and the other half received the current best standard treatment. All participants received active treatment for their cancer. |
|
FINDINGS |
Findings from the ENZAMET trial have shown that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone-sensitive prostate cancer, and men with this sort of cancer who receive enzalutamide with standard treatment have a 33% improvement in overall survival and a 60%improvement in progression-free survival, compared to men receiving standard treatment alone. |
|
EXPERTISE |
Conceived, designed and conducted in collaboration with ANZUP. Large multi-national trial run over 10 years with the majority of sites based in the USA. |
|
DURATION |
2014 - 2021 |
|
COLLABORATORS |
ANZUP, Canadian Cancer Trials Group (CCTG), Dana-Faber Cancer Institute, Cancer Trials Ireland |
|
FURTHER READING |
Full trial details on ANZCTR > Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer |